Leading French generic drug company Biogaran launches its operations in Mali and strengthens its presence in Africa

Bamako, Mali, February 24, 2020

The French pharmaceutical laboratory Biogaran, leader of the generic medicines market in France, announces the start of its commercial activities in Mali. This launch is a continuation of a series of commercial deployments in Ivory Coast, Congo-Brazzaville and Gabon in 2019, as well as in Senegal in February 2020 and allows the laboratory to strengthen its commitment in favor of high-quality medicines at an affordable price.

m3fb5llcj8-image-20200224144434-2.jpeg

From left to right: Dr Badra Aliou Wade (President of the Inter-Order of Health of Mali), Mr. Sidy Diallo (Chief of Staff of the Minister of Health and Social Affairs), Pr. Hamar Alassane Traoré (Speaker), Mr. Valery Alves (Head of the Economic Service of the French Embassy in Mali), Dr. Cheickna Hamala Fofana (Regional Director Mali of Biogaran)

Biogaran, a subsidiary of the Servier group specializing in generic drugs, has officially launched its commercial activities in Mali. The inaugural ceremony took place on Friday, February the 21st of 2020, at the Sheraton hotel of Bamako, in the presence of 140 guests, including Sidy Diallo, Chief of Staff of the Minister of Health and Social Affairs, Valery Alves, Head of the Economic Service of the French Embassy in Mali, Dr. Aliou Badra Wade, President of the Inter-Order of Health of Mali and Dr. Cheickna Hamala Fofana, Regional Director Mali of Biogaran.

In Mali, Biogaran provides patients with 22 generic bioequivalent drugs from 6 distinct therapeutic areas, covering common pathologies such as hypertension, diabetes, bacterial infections and even diarrhea. By providing patients of Mali with these bioequivalent generic medicines imported from France at an affordable price, Biogaran is contributing to meet the challenges of accessibility of medicines in Mali, considered as a priority by the Malian government in its Ten-Year Health and Social Development Plan (2014–2023). The laboratory also aims at marketing 10 new drugs each year in order to increase the availability of essential and high-quality drugs on the territory.

Moreover, Biogaran is committed to supporting health professionals and patients in the delivery and management of treatments. A pharmacist based in Abidjan is available to collect pharmacovigilance cases and provide healthcare professionals with quality medical information on Biogaran drugs. In addition, therapeutic education tools will be made available to inform and support patients in their treatment.

pbjfh8xpc9-image-20200224144422-1.jpeg

Nearly 150 people attended the official launching ceremony of Biogaran's commercial activities in Mali

The development of Biogaran in Mali also aims for combatting the proliferation of counterfeit medicines, mainly present in sub-Saharan Africa where they cause nearly 100,000 deaths each year, according to the WHO. In this context, the Biogaran laboratory is committed to supplying patients in Mali with affordable and safe generic medicines, directly imported from France, where it treats 27 million patients every day. Also, its tamper-proof packaging guarantees patients the intake of a quality drug, manufactured in strict compliance with European standards.

Dr. Cheickna Hamala Fofana, Regional Director Mali of Biogaran said: “By proposing to patients in Mali bio-equivalent medicines identical to those we propose every day to our 27 million patients in France, we want to contribute to the fight against counterfeit medicines while promoting the democratization of high-quality generic medicines. Our commitment to universal access to high-quality healthcare takes on meaning as we strengthen our presence in West and Central Africa.”

k0ogemy3ut-image-20200224144839-1.jpeg

From left to right: Dr. Cheickna Hamala Fofana (Regional Director Mali of Biogaran) and Mr. Sidy Diallo (Chief of Staff of the Minister of Health and Social Affairs of Mali)

The Chief of Staff of the Minister of Health and Social Affairs Sidy Diallo added: "Access to quality medicines is an imperative in Mali. Our authorities have grasped the magnitude of the problem of fake medicines, a public health issue to which we are determined to respond in a firm, resolute, and effective manner. In this task that we have set ourselves, the support of the Biogaran laboratory is welcome and we will support them in their development on our territory, for the well-being of patients in Mali."

2019 was marked by the development of Biogaran activities in West and Central Africa, and more particularly in Côte d'Ivoire, Congo-Brazzaville and Gabon. This phase of expansion in Africa, initiated in 2017 with the acquisition of the Swipha laboratory in Nigeria and pursued in 2020 with the deployment of its commercial activities in Senegal and then in Mali, testifies to Biogaran's desire to provide patients in sub-Saharan Africa high-quality and safe healthcare at a fair price.

Biogaran is a French pharmaceutical laboratory specialized in generic drugs, a subsidiary of Servier and headquartered in Colombes (France). Founded in 1996, it is now the French leader in generic drugs. In 2019, Biogaran generated gross sales of €1.360 billion with more than 300 million units sold. Internationally, the group is present in Brazil through Pharlab. The acquisition of Swipha in 2017, a Nigerian generic drug laboratory, marked its first operation in Africa.

More information: www.biogaran.fr

Contacts

Asset

Linked topic

Related links